BioLineRx (BLRX) Depreciation & Amortization (CF) (2014 - 2026)
BioLineRx (BLRX) posted quarterly Depreciation & Amortization (CF) of $63000.0 for Q4 2025, down 96.6% year-over-year from $1.9 million in Q4 2024, and down 47.06% quarter-over-quarter from $119000.0 in Q3 2025.
Powered by 
Analysis
BioLineRx (BLRX) Depreciation & Amortization (CF) (2014 - 2026) Analysis & Trends
BioLineRx's Depreciation & Amortization (CF) history runs 12 years deep, the most recent figure standing at $63000.0 for Q4 2025.
- In Q4 2025, Depreciation & Amortization (CF) fell 96.6% year-over-year to $63000.0; the TTM figure through Dec 2025 stood at $523000.0 (down 87.13% YoY), while the FY2025 annual figure was $523000.0, down 87.13% from the prior year.
- Depreciation & Amortization (CF) for Q4 2025 stood at $63000.0, down from $119000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $1.9 million in Q4 2024, with the low at $63000.0 in Q4 2025.
- The 5-year median for Depreciation & Amortization (CF) is $181000.0 (2021), against an average of $366450.0.
- The sharpest annual moves came in 2024 and 2025: Depreciation & Amortization (CF) surged 280.09% in 2024, then tumbled 96.6% in 2025.
- BioLineRx's Depreciation & Amortization (CF) stood at $174000.0 in 2021, then gained by 7.47% to $187000.0 in 2022, then jumped by 277.54% to $706000.0 in 2023, then jumped by 162.32% to $1.9 million in 2024, then sank by 96.6% to $63000.0 in 2025.
- Business Quant data shows BLRX's Depreciation & Amortization (CF) at $63000.0 in Q4 2025, $119000.0 in Q3 2025, and $176000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | BioLineRx | 6.64 Bn | 6.64 Bn | 235,000.00 | 78,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 78,000.00 |
| Mar 31, 2026 | 88,000.00 |
| Dec 31, 2025 | 63,000.00 |
| Sep 30, 2025 | 119,000.00 |
| Mar 31, 2025 | 165,000.00 |
| Dec 31, 2024 | 1.85 Mn |
| Sep 30, 2024 | 840,000.00 |
| Jun 30, 2024 | 482,000.00 |
| Mar 31, 2024 | 897,000.00 |
| Dec 31, 2023 | 706,000.00 |
| Sep 30, 2023 | 221,000.00 |
| Jun 30, 2023 | 198,000.00 |
| Mar 31, 2023 | 259,000.00 |
| Dec 31, 2022 | 187,000.00 |
| Sep 30, 2022 | 153,000.00 |
| Jun 30, 2022 | 141,000.00 |
| Mar 31, 2022 | 173,000.00 |
| Dec 31, 2021 | 174,000.00 |
| Sep 30, 2021 | 167,000.00 |
| Jun 30, 2021 | 180,000.00 |